Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: Medicinal chemistry and preclinical aspects

Current Medicinal Chemistry

Volumn 19, Issue 23, 2012, Pages 3982-3999

  Liu, Y ^a   Hu, Y ^a   Liu, T ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Analogs; DPP 4; Drug design; Inhibitors; Medicinal chemistry; Non peptidomimetic; Preclinical; SAR; Selectivity; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; CARMEGLIPTIN; DA 1229; DIPEPTIDYL PEPTIDASE IV INHIBITOR; E 3024; GLUCOSE; LINAGLIPTIN; SITAGLIPTIN; TAK 100; UNCLASSIFIED DRUG;

ARTICLE; DOSE RESPONSE; DRUG APPROVAL; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG MARKETING; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HUMAN; IC 50; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOPHORE; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

AMINES; CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPOGLYCEMIC AGENTS; ORGANOPHOSPHORUS COMPOUNDS; PEPTIDOMIMETICS; PIPERIDONES; QUINOLIZINES; XANTHINES;

EID: 84865785890     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712802002491     Document Type: Article

References (102)

1. International Diabetes Federation. Diabetes Atlas. http://www.eatlas.idf. org/ (accessed 18 October 2008).
2. Mizuno, C. S.; Chittiboyina, A. G.; Kurtz, T. W.; Pershadsingh, H. A.; Avery, M. A. Type 2 diabetes and oral antihyperglycemic drugs. Curr. Med. Chem., 2008, 15 (1), 61-74. (Pubitemid 351234628)
3. Srinivasan, B. T.; Jarvis, J.; Khunti, K.; Davies, M. J. Recent advances in the managementof type 2 diabetes mellitus: a review. Postgrad. Med. J., 2008, 84 (996), 524-531.
4. Mohler, M. L.; He, Y.; Wu, Z.; Hwang, D. J.; Miller, D. D. Recent and emerging anti-diabetes targets. Med. Res. Rev., 2009, 29 (1), 125-195.
5. Kieffer, T. J.; Habener, J. F. The glucagon-like peptides. Endocr. Rev., 1999, 20 (6), 876-913. (Pubitemid 30647076)
6. Drucker, D. J. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin. Investig. Drugs, 2003, 12 (1), 87-100. (Pubitemid 36104645)
7. Weber, A. E. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J. Med. Chem., 2004, 47 (17), 4135-4141. (Pubitemid 39045417)
8. Deacon, C. F.; Ahren, B.; Holst, J. J. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opin. Investig. Drugs, 2004, 13 (9), 1091-1102. (Pubitemid 39242733)
9. Demuth, H. U.; McIntosh, C. H.; Pederson, R. A. Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors. Biochim. Biophys. Acta., 2005, 1751 (1), 33-44. (Pubitemid 41033292)
10. Barnett, A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int. J. Clin. Pract., 2006, 60 (11), 1454-1470. (Pubitemid 44560347)
11. Sebokova, E.; Christ, A. D.; Boehringer, M.; Mizrahi, J. Dipeptidyl peptidase IV inhibitors: the next generation of new promising therapies for the management of type 2 diabetes. Curr. Top. Med. Chem., 2007, 7 (6), 547-555. (Pubitemid 46488279)
12. Hunziker, D.; Hennig, M.; Peters, J. U. Inhibitors of dipeptidyl peptidase IV -Recent advances and structural views. Curr. Top. Med. Chem., 2005, 5 (16), 1623-1637.
13. Gwaltney, S. L.; Stafford, J. A. Inhibitors of dipeptidyl peptidase 4. Annu. Rep. Med. Chem., 2005, 40, 149-165. (Pubitemid 44262129)
14. Wiedeman, P. E. DPPIV inhibition: promising therapy for the treatment of type 2 diabetes. Prog. Med. Chem., 2007, 45, 63-109.
15. Gwaltney, S. L. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV. Curr. Top. Med. Chem., 2008, 8 (17), 1545-1552.
16. Pei, Z. From the bench to the bedside: Dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Curr. Opin. Drug Discov. Devel., 2008, 11 (4), 512-532. (Pubitemid 351950846)
17. Salvatore, T.; Carbonara, O.; Cozzolino, D.; Torella, R.; Sasso, F. C. Progress in the oral treatment of type 2 diabetes: update on DPP-IV inhibitors. Curr. Diabetes. Rev., 2009, 5 (2), 92-101.
18. Havale, S. H.; Pal, M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg. Med. Chem., 2009, 17 (5), 1783-1802.
19. Gupta, R.; Walunj, S. S.; Tokala, R. K.; Parsa, K. V.; Singh, S. K.; Pal, M. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr. Drug. Targets., 2009, 10 (1), 71-87.
20. Weber, A. E., Thornberry, N. A. Burger's Medicinal Chemistry, Drug Discovery, and Development, 7th ed.; Wiley & Sons: New York, 2010.
21. Chen, S. J.; Jiaang, W. T. Current Advances and Therapeutic Potential of Agents Targeting Dipeptidyl Peptidases-IV, -II, 8/9 and Fibroblast Activation Protein. Curr. Top. Med. Chem., 2011, 11 (12), 1447-1463.
22. Peters, J. U. 11 Years of cyanopyrrolidines as DPP-IV inhibitors. Curr. Top. Med. Chem., 2007, 7 (6), 579-595.
23. Ferraris, D.; Belyakov, S.; Li, W.; Oliver, E.; Ko, Y. S.; Calvin, D.; Lautar, S.; Thomas, B.; Rojas, C. Azetidine-based inhibitors of dipeptidyl peptidase IV (DPP IV). Curr. Top. Med. Chem., 2007, 7 (6), 597-608. (Pubitemid 46488282)
24. Gallwitz, B. Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy. Expert Opin. Investig. Drugs., 2011, 20 (6), 723-732.
25. Mendieta, L.; Tarrago, T.; Giralt, E. Recent patents of dipeptidyl peptidase IV inhibitors. Expert Opin. Ther. Pat., 2011, 21 (11), 1693-1741.
26. Lankas, G. R.; Leiting, B.; Roy, R. S.; Eiermann, G. J.; Beconi, M. G.; Biftu, T.; Chan, C. C.; Edmondson, S.; Feeney, W. P.; He, H.; Ippolito, D. E.; Kim, D.; Lyons, K. A.; Ok, H. O.; Patel, R. A.; Petrov, A. N.; Pryor, K. A.; Qian, X.; Reigle, L.; Woods, A.; Wu, J. K.; Zaller, D.; Zhang, X.; Zhu, L.; Weber, A. E.; Thornberry, N. A. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes, 2005, 54 (10), 2988-2994. (Pubitemid 41401097)
27. Rasmussen, H. B.; Branner, S.; Wiberg, F. C.; Wagtmann, N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat. Struct. Biol., 2003, 10 (1), 19-25. (Pubitemid 36034172)
28. Kuhn, B.; Hennig, M.; Mattei, P. Molecular recognition of ligands in dipeptidyl peptidase IV. Curr. Top. Med. Chem., 2007, 7 (6), 609-619. (Pubitemid 46488283)
29. Mulakayala, N.; Reddy, UC.; Iqbal, J.; Pal, M. Synthesis of dipeptidyl peptidase-4 inhibitors: a brief overview. Tetrahedron, 2010, 66 (27-28), 4919-4938.
30. Szczepankiewicz, B. G.; Kurukulasuriya, R. Aromatic heterocycle-based DPP-IV inhibitors: xanthines and related structural types. Curr. Top. Med. Chem., 2007, 7 (6), 569-578. (Pubitemid 46488281)
31. Kanstrup, A. B.; Christiansen, L. B.; Lundbeck, J. M.; Sams, C. K.; Kristiansen, M. Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV. W.O. Patent 0, 202, 560, January 10, 2002.
32. Himmelsbach, F.; Mark, M.; Eckhardt, M.; Landkopf, E.; Maier, R.; Lotz, R. Xanthine derivative, production and use thereof as a medicament. W.O. Patent 02, 068, 420, September 6, 2002.
33. Kurukulasuriya, R.; Rohde, J. J.; Szczepankiewicz, B. G.; Basha, F.; Lai, C.; Jae, H. S.; Winn, M.; Stewart, K. D.; Longenecker, K. L.; Lubben, T. W.; Ballaron, S. J.; Sham, H. L.; von Geldern, T. W. Xanthine mimetics as potent dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2006, 16 (24), 6226-6230. (Pubitemid 44709915)
34. Eckhardt, M.; Langkopf, E.; Mark, M.; Tadayyon, M.; Thomas, L.; Nar, H.; Pfrengle, W.;Guth, B.; Lotz, R.; Sieger, P.; Fuchs, H.; Himmelsbach, F. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2- ylmethyl)-3, 7-dihydropurine-2, 6-dione (BI 1356), a highlypotent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2007, 50 (26), 6450-6453. (Pubitemid 350309082)
35. Rungby, J. Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes. Expert Opin. Investig. Drugs, 2009, 18 (6), 835-838.
36. Baetta, R.; Corsini, A. Pharmacology of dipeptidyl peptidase-4 inhibitors similarities and differences. Drugs, 2011, 71 (11), 1441-1467.
37. Huttner, S.; Graefe-Mody, EU.; Withopf, B.; Ring, A.; Dugi, KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J. Clin. Pharmacol., 2008, 48 (10), 1171-1178.
38. Nishio, Y.; Kimura, H.; Tosaki, S.; Sugaru, E.; Sakai, M.; Horiguchi, M.; Masui, Y.; Ono, M.; Nakagawa, T.; Nakahira, H. Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore. Bioorg. Med. Chem. Lett., 2010, 20 (24), 7246-7249.
39. Nishio, Y.; Kimura, H.; Sawada, N.; Sugaru, E.; Horiguchi, M.; Ono, M.; Furuta, Y.; Sakai, M.; Masui, Y.; Otani, M.; Hashizuka, T.; Honda, Y.; Deguchi, J.; Nakagawa, T.; Nakahira, H. 2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1, 3-dimethyl-2, 4-dioxo-1, 2, 3, 4-tetrahydro-5Hpyrrolo[ 3, 2-d]pyrimidine-5-yl} methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanismbased inactivation of CYP3A. Bioorg. Med. Chem., 2011, 19 (18), 5490-5499.
40. Eckhardt, M.; Hauel, N.; Himmelsbach, F.; Langkopf, E.; Nar, H.; Mark, M.; Tadayyon, M.;Thomas, L.; Guth, B.; Lotz, R. 3, 5-Dihydro-imidazo[4, 5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors. Bioorg. Med. Chem. Lett., 2008, 18 (11), 3158-3162. (Pubitemid 351718346)
41. Yamazaki, K.; Yasuda, N.; Inoue, T.; Nagakura, T.; Kira, K.; Shinoda, M.; Saeki, T.; Tanaka, I. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl- 7, 9-dihydro-purin-8-one is a nove competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity. J. Pharmacol. Exp. Ther., 2006, 319 (3), 1253-1257.
42. Yasuda, N.; Nagakura, T.; Inoue, T.; Yamazaki, K.; Katsutani, N.; Takenaka, O.; Clark, R.;Matsuura, F.; Emori, E.; Yoshikawa, S.; Kira, K.; Ikuta, H.; Okada, T.; Saeki, T.; Asano, O.; Tanaka, I. E3024, 3-but-2-ynyl-5-methyl-2- piperazin-1-yl-3, 5-dihydro-4H-imidazo[4, 5-d]pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor. Eur. J. Pharmacol., 2006, 548 (1-3), 181-187. (Pubitemid 44397020)
43. Feng, J.; Zhang, Z.; Wallace, M. B.; Stafford, J. A.; Kaldor, S. W.; Kassel, D. B.; Navre, M.; Shi, L.; Skene, R. J.; Asakawa, T.; Takeuchi, K.; Xu, R.; Webb, D. R.; Gwaltney, S. L. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J. Med. Chem., 2007, 50 (10), 2297-2300. (Pubitemid 46799241)
44. Deng, J.; Peng, L.; Zhang, G.; Lan, X.; Li, C.; Chen, F.; Zhou, Y.; Lin, Z.; Chen, L.; Dai, R.; Xu, H.; Yang, L.; Zhang, X.; Hu, W. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes. Eur. J. Med. Chem., 2011, 46 (1), 71-76.
45. Zhang, Z.; Wallace, M. B.; Feng, J.; Stafford, J. A.; Skene, R. J.; Shi, L.; Lee, B.; Aertgeerts, K.; Jennings, A.; Xu, R.; Kassel, D. B.; Kaldor, S. W.; Navre, M.; Webb, D. R.; Gwaltney, S. L. Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV. J. Med. Chem., 2011, 54 (2), 510-524.
46. Parsa, K. V.; Pal, M. Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview. Expert Opin. Drug Discov., 2011, 6 (8), 855-869.
47. Deacon, C. F. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Curr. Opin. Investig. Drugs., 2008, 9 (4), 402-413. (Pubitemid 351507666)
48. Kodimuthali, A.; Prasunamba, P. L.; Pal, M. Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: Introduction of a spirocyclic moiety on the piperidine ring. Beilstein J. Org. Chem., 2010, 6. 1-5.
49. Xu, J.; Ok, H. O.; Gonzalez, E. J.; Colwell, L. F., Jr.; Habulihaz, B.; He, H.; Leiting, B.; Lyons, K. A.; Marsilio, F.; Patel, R. A.; Wu, J. K.; Thornberry, N. A.; Weber, A. E.; Parmee, E. R. Discovery of potent and selective betahomophenylalanine based dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2004, 14 (18), 4759-4762. (Pubitemid 39490304)
50. Brockunier, L. L.; He, J.; Colwell, L. F., Jr.; Habulihaz, B.; He, H.; Leiting, B.; Lyons, K. A.; Marsilio, F.; Patel, R. A.; Teffera, Y.; Wu, J. K.; Thornberry, N. A.; Weber, A. E.; Parmee, E. R. Substituted piperazines as novel dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2004, 14 (18), 4763-4766. (Pubitemid 39490305)
51. Thornberry, N. A.; Weber, A. E. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr. Top. Med. Chem., 2007, 7 (6), 557-568. (Pubitemid 46488280)
52. Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H.; Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M. E.; Patel, R. A.; Petrov, A.; Scapin, G.; Patel, S. B.; Roy, R. S.; Wu, J. K.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber, A. E. (2R)-4-oxo-4-[3-(trifluoromethyl)-5, 6-dihydro[1, 2, 4]triazolo[4, 3-a]pyrazin-7(8H)-yl]-1-(2, 4, 5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2005, 48 (1), 141-151. (Pubitemid 40105255)
53. Kim, D.; Kowalchick, J. E.; Edmondson, S. D.; Mastracchio, A.; Xu, J.; Eiermann, G. J.; Leiting, B.; Wu, J. K.; Pryor, K. D.; Patel, R. A.; He, H.; Lyons, K. A.; Thornberry, N. A.; Weber, A. E. Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate). Bioorg. Med. Chem. Lett., 2007, 17 (12), 3373-3377. (Pubitemid 46819031)
54. Kim, D.; Kowalchick, J. E.; Brockunier, L. L.; Parmee, E. R.; Eiermann, G. J.; Fisher, M. H.; He, H.; Leiting, B.; Lyons, K.; Scapin, G.; Patel, S. B.; Petrov, A.; Pryor, K. D.; Roy, R. S.; Wu, J. K.; Zhang, X.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber, A. E. Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from betaaminoamides bearing subsituted triazolopiperazines. J. Med. Chem., 2008, 51 (3), 589-602. (Pubitemid 351252287)
55. Nordhoff, S.; Cerezo-Galvez, S.; Feurer, A.; Hill, O.; Matassa, V. G.; Metz, G.; Rummey, C.; Thiemann, M.; Edwards, P. J. The reversed binding of beta-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors. Bioorg. Med. Chem. Lett., 2006, 16 (6), 1744-1748. (Pubitemid 43197558)
56. Nordhoff, S.; Cerezo-Galvez, S.; Deppe, H.; Hill, O.; Lopez-Canet, M.; Rummey, C.; Thiemann, M.; Matassa, V. G.; Edwards, P. J.; Feurer, A. Discovery of beta-homophenylalanine based pyrrolidin-2-ylmethyl amides and sulfonamides as highly potent and selective inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett., 2009, 19 (15), 4201-4203.
57. Nordhoff, S.; Lopez-Canet, M.; Hoffmann-Enger, B.; Bulat, S.; Cerezo-Galvez, S.; Hill, O.; Rosenbaum, C.; Rummey, C.; Thiemann, M.; Matassa, V. G.; Edwards, P. J.; Feurer, A. From lead to preclinical candidate: optimization of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett., 2009, 19 (16), 4818-4823.
58. Nordhoff, S.; Bulat, S.; Cerezo-Galvez, S.; Hill, O.; Hoffmann-Enger, B.; Lopez-Canet, M.; Rosenbaum, C.; Rummey, C.; Thiemann, M.; Matassa, V. G.; Edwards, P. J.; Feurer, A. The design of potent and selective inhibitors of DPP-4: optimization of ADME properties by amide replacements. Bioorg. Med. Chem. Lett., 2009, 19 (22), 6340-6345.
59. Park, W. S.; Kang, S. K.; Jun, M. A.; Shin, M. S.; Kim, K. Y.; Rhee, S. D.; Bae, M. A.; Kim, M. S.; Kim, K. R.; Kang, N. S.; Yoo, S. E.; Lee, J. O.; Song, D. H.; Silinski, P.; Schneider, S. E.; Ahn, J. H.; Kim, S. S. Discovery of beta-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2011, 21 (5), 1366-1370.
60. Jun, M. A.; Park, W. S.; Kang, S. K.; Kim, K. Y.; Kim, K. R.; Rhee, S. D.; Bae, M. A.; Kang, N. S.; Sohn, S. K.; Kim, S. G.; Lee, J. O.; Lee, D. H.; Cheon, H. G.; Kim, S. S.; Ahn, J. H. Synthesis and biological evaluation of pyrazoline analogues with beta-amino acyl group as dipeptidyl peptidase IV inhibitors. Eur. J. Med. Chem., 2008, 43 (9), 1889-1902.
61. Nitta, A.; Fujii, H.; Sakami, S.; Nishimura, Y.; Ohyama, T.; Satoh, M.; Nakaki, J.; Satoh, S.; Inada, C.; Kozono, H.; Kumagai, H.; Shimamura, M.; Fukazawa, T.; Kawai, H. (3R)-3-amino-4-(2, 4, 5-trifluorophenyl)-N-{4-[6-(2- methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide as a potent dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett., 2008, 18 (20), 5435-5438.
62. Kim, H. J.; Kwak, W. Y.; Min, J. P.; Lee, J. Y.; Yoon, T. H.; Kim, H. D.; Shin, C. Y.; Kim, M. K.; Choi, S. H.; Kim, H. S.; Yang, E. K.; Cheong, Y. H.; Chae, Y. N.; Park, K. J.; Jang, J. M.; Choi, S. J.; Son, M. H.; Kim, S. H.; Yoo, M.; Lee, B. J. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett., 2011, 21 (12), 3809-3812.
63. Park, M.; Kim, T.; Shin, K.; Yoon, S.; Cho, J.; Jang, I.; Yu, K.; Shin, S. Pharmacokinetics and pharmacodynamics of DA-1229, a novel dipeptidyl peptidase (DPP) IV inhibitor, after single or multiple dosing in healthy volunteers. Clin. Pharmacol. Ther., 2011, 89 (1), S13-S13.
64. Liang, G. B.; Qian, X.; Feng, D.; Biftu, T.; Eiermann, G.; He, H.; Leiting, B.; Lyons, K.; Petrov, A.; Sinha-Roy, R.; Zhang, B.; Wu, J.; Zhang, X.; Thornberry, N. A.; Weber, A. E. Optimization of 1, 4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett., 2007, 17 (7), 1903-1907. (Pubitemid 46367675)
65. Biftu, T.; Feng, D.; Qian, X.; Liang, G. B.; Kieczykowski, G.; Eiermann, G.; He, H.; Leiting, B.; Lyons, K.; Petrov, A.; Sinha-Roy, R.; Zhang, B.; Scapin, G.; Patel, S.; Gao, Y. D.; Singh, S.; Wu, J.; Zhang, X.; Thornberry, N. A.; Weber, A. E. (3R)-4-[(3R)-3-Amino-4-(2, 4, 5-trifluorophenyl)butanoyl]-3-(2, 2, 2-trifluoro ethyl)-1, 4-diazepan-2-one, a selective dipeptidyl peptidas IV inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett., 2007, 17 (1), 49-52. (Pubitemid 44959987)
66. Ahn, J. H.; Shin, M. S.; Jun, M. A.; Jung, S. H.; Kang, S. K.; Kim, K. R.; Rhee, S. D.; Kang, N. S.; Kim, S. Y.; Sohn, S. K.; Kim, S. G.; Jin, M. S.; Lee, J. O.; Cheon, H. G.; Kim, S. S. Synthesis, biological evaluation and structural determination of beta-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors. Bioorg. Med. Chem. Lett., 2007, 17 (9), 2622-2628. (Pubitemid 46509838)
67. Ahn, J. H.; Jun, M. A.; Shin, M. S.; Park, W. S.; Kang, S. K.; Kim, K. Y.; Rhee, S. D.; Lee, D. H.; Cheon, H. G.; Kim, S. S. SAR Study of beta-Aminoacyl-Containing Cyclic Hydrazide Derivatives as DPP-IV Inhibitors. Bull. Korean Chem. Soc., 2008, 29 (11), 2129-2134.
68. Ahn, J. H.; Park, W. S.; Jun, M. A.; Shin, M. S.; Kang, S. K.; Kim, K. Y.; Rhee, S. D.; Bae, M. A.; Kim, K. R.; Kim, S. G.; Kim, S. Y.; Sohn, S. K.; Kang, N. S.; Lee, J. O.; Lee, D. H.; Cheon, H. G.; Kim, S. S. Synthesis and biological evaluation of homopiperazine derivatives with beta-aminoacyl group as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2008, 18 (24), 6525-6529.
69. Chen, P.; Caldwell, C. G.; Mathvink, R. J.; Leiting, B.; Marsilio, F.; Patel, R. A.; Wu, J. K.; He, H.; Lyons, K. A.; Thornberry, N. A.; Weber, A. E. Imidazopiperidine amides as dipeptidyl peptidase IV inhibitors for the treatment of diabetes. Bioorg. Med. Chem. Lett., 2007, 17 (21), 5853-5857. (Pubitemid 47446221)
70. Kowalchick, J. E.; Leiting, B.; Pryor, K. D.; Marsilio, F.; Wu, J. K.; He, H.; Lyons, K. A.; Eiermann, G. J.; Petrov, A.; Scapin, G.; Patel, R. A.; Thornberry, N. A.; Weber, A. E.; Kim, D. Design, synthesis, and biological evaluation of triazolopiperazine-based beta-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors. Bioorg. Med. Chem. Lett., 2007, 17 (21), 5934-5939. (Pubitemid 47446206)
71. Shan, Z.; Peng, M.; Fan, H.; Lu, Q.; Lu, P.; Zhao, C.; Chen, Y. Discovery of potent dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing substituted [1, 2, 3]-triazolopiperidines for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett., 2011, 21 (6), 1731-1735.
72. Zhu, Y.; Xia, S.; Zhu, M.; Yi, W.; Cheng, J.; Song, G.; Li, Z.; Lu, P. Synthesis, biological assay in vitro and molecular docking studies of new imidazopyrazinone derivatives as potential dipeptidyl peptidase IV inhibitors. Eur. J. Med. Chem., 2010, 45 (11), 4953-4962.
73. Benbow, J. W.; Andrews, K. A.; Aubrecht, J.; Beebe, D.; Boyer, D.; Doran, S.; Homiski, M.; Hui, Y.; McPherson, K.; Parker, J. C.; Treadway, J.; Vanvolkenberg, M.; Zembrowski, W. J. Piperidinyl-2-phenethylamino inhibitors of DPP-IV for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett., 2009, 19 (8), 2220-2223.
74. Chen, P.; Caldwell, C. G.; Ashton, W.; Wu, J. K.; He, H.; Lyons, K. A.; Thornberry, N. A.; Weber, A. E. Synthesis and evaluation of [(1R)-1-amino-2-(2, 5-difluorophenyl)ethyl]cyclohexanes and 4-[(1R)-1-amino-2-(2, 5-difluorophenyl)ethyl]piperidines as DPP-4 inhibitors. Bioorg. Med. Chem. Lett., 2011, 21 (6), 1880-1886.
75. Pei, Z.; Li, X.; von Geldern, T. W.; Madar, D. J.; Longenecker, K.; Yong, H.; Lubben, T. H.; Stewart, K. D.; Zinker, B. A.; Backes, B. J.; Judd, A. S.; Mulhern, M.; Ballaron, S. J.; Stashko, M. A.; Mika, A. K.; Beno, D. W.; Reinhart, G. A.; Fryer, R. M.; Preusser, L. C.; Kempf-Grote, A. J.; Sham, H. L.; Trevillyan, J. M. Discovery of ((4R, 5S)-5-amino-4-(2, 4, 5-trifluorophenyl) cyclohex-1-enyl)-(3-(trifluoromethyl)-5, 6-dihydro-[1, 2, 4]triazolo[4, 3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2006, 49 (22), 6439-6442. (Pubitemid 44657439)
76. Biftu, T.; Scapin, G.; Singh, S.; Feng, D.; Becker, J. W.; Eiermann, G.; He, H.; Lyons, K.; Patel, S.; Petrov, A.; Sinha-Roy, R.; Zhang, B.; Wu, J.; Zhang, X.; Doss, G. A.; Thornberry, N. A.; Weber, A. E. Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin. Bioorg. Med. Chem. Lett., 2007, 17 (12), 3384-3387. (Pubitemid 46819024)
77. Gao, Y. D.; Feng, D.; Sheridan, R. P.; Scapin, G.; Patel, S. B.; Wu, J. K.; Zhang, X.; Sinha-Roy, R.; Thornberry, N. A.; Weber, A. E.; Biftu, T. Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors. Bioorg. Med. Chem. Lett., 2007, 17 (14), 3877-3879. (Pubitemid 46920945)
78. Backes, B. J.; Longenecker, K.; Hamilton, G. L.; Stewart, K.; Lai, C.; Kopecka, H.; von Geldern, T. W.; Madar, D. J.; Pei, Z.; Lubben, T. H.; Zinker, B. A.; Tian, Z.; Ballaron, S. J.; Stashko, M. A.; Mika, A. K.; Beno, D. W.; Kempf-Grote, A. J.; Black-Schaefer, C.; Sham, H. L.; Trevillyan, J. M. Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit. Bioorg. Med. Chem. Lett., 2007, 17 (7), 2005-2012. (Pubitemid 46367663)
79. Wright, S. W.; Ammirati, M. J.; Andrews, K. M.; Brodeur, A. M.; Danley, D. E.; Doran, S. D.; Lillquist, J. S.; Liu, S.; McClure, L. D.; McPherson, R. K.; Olson, T. V.; Orena, S. J.; Parker, J. C.; Rocke, B. N.; Soeller, W. C.; Soglia, C. B.; Treadway, J. L.; Vanvolkenburg, M. A.; Zhao, Z.; Cox, E. D. (3R, 4S)-4-(2, 4, 5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization. Bioorg. Med. Chem. Lett., 2007, 17 (20), 5638-5642. (Pubitemid 47391309)
80. Andrews, K. M.; Beebe, D. A.; Benbow, J. W.; Boyer, D. A.; Doran, S. D.; Hui, Y.; Liu, S.; McPherson, R. K.; Neagu, C.; Parker, J. C.; Piotrowski, D. W.; Schneider, S. R.; Treadway, J. L.; VanVolkenberg, M. A.; Zembrowski, W. J. 1-((3S, 4S)-4-amino-1-(4-substituted-1, 3, 5-triazin-2-yl) pyrrolidin-3-yl)-5, 5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett., 2011, 21 (6), 1810-1814.
81. Pei, Z.; Li, X.; von Geldern, T. W.; Longenecker, K.; Pireh, D.; Stewart, K. D.; Backes, B. J.; Lai, C.; Lubben, T. H.; Ballaron, S. J.; Beno, D. W.; Kempf-Grote, A. J.; Sham, H. L.; Trevillyan, J. M. Discovery and structureactivity relationships of piperidinone-and piperidine-constrained phenethylamines as novel, potent, and selective dipeptidyl peptidase IV inhibitors. J. Med. Chem., 2007, 50 (8), 1983-1987. (Pubitemid 46626607)
82. Cox, J. M.; Harper, B.; Mastracchio, A.; Leiting, B.; Sinha Roy, R.; Patel, R. A.; Wu, J. K.; Lyons, K. A.; He, H.; Xu, S.; Zhu, B.; Thornberry, N. A.; Weber, A. E.; Edmondson, S. D. Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2007, 17 (16), 4579-4583. (Pubitemid 47058943)
83. Edmondson, S. D.; Mastracchio, A.; Cox, J. M.; Eiermann, G. J.; He, H.; Lyons, K. A.; Patel, R. A.; Patel, S. B.; Petrov, A.; Scapin, G.; Wu, J. K.; Xu, S.; Zhu, B.; Thornberry, N. A.; Roy, R. S.; Weber, A. E. Aminopiperidinefused imidazoles as dipeptidyl peptidase-IV inhibitors. Bioorg. Med. Chem. Lett., 2009, 19 (15), 4097-4101.
84. Peters, J. U.; Hunziker, D.; Fischer, H.; Kansy, M.; Weber, S.; Kritter, S.; Muller, A.; Wallier, A.; Ricklin, F.; Boehringer, M.; Poli, S. M.; Csato, M.; Loeffler, B. M. An aminomethylpyrimidine DPP-IV inhibitor with improved properties. Bioorg. Med. Chem. Lett., 2004, 14 (13), 3575-3578. (Pubitemid 38737170)
85. Peters, J. U.; Weber, S.; Kritter, S.; Weiss, P.; Wallier, A.; Boehringer, M.; Hennig, M.; Kuhn, B.; Loeffler, B. M. Aminomethylpyrimidines as novel DPP-IV inhibitors: a 10(5)-fold activity increase by optimization of aromatic substituents. Bioorg. Med. Chem. Lett., 2004, 14 (6), 1491-1493. (Pubitemid 38299435)
86. Brigance, R. P.; Meng, W.; Fura, A.; Harrity, T.; Wang, A.; Zahler, R.; Kirby, M. S.; Hamann, L. G. Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes. Bioorg. Med. Chem. Lett., 2010, 20 (15), 4395-4398.
87. Meng, W.; Brigance, R. P.; Chao, H. J.; Fura, A.; Harrity, T.; Marcinkeviciene, J.; O'Connor, S. P.; Tamura, J. K.; Xie, D.; Zhang, Y.; Klei, H. E.; Kish, K.; Weigelt, C. A.; Turdi, H.; Wang, A.; Zahler, R.; Kirby, M. S.; Hamann, L. G. Discovery of 6-(aminomethyl)-5-(2, 4-dichlorophenyl)-7- methylimidazo[1, 2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J. Med. Chem., 2010, 53 (15), 5620-5628.
88. Peters, J. U.; Weber, S.; Kritter, S.; Weiss, P.; Wallier, A.; Zimmerli, D.; Boehringer, M.; Steger, M.; Loeffler, B. M. Aminomethylpyridines as DPPIV inhibitors. Bioorg. Med. Chem. Lett., 2004, 14 (13), 3579-3580.
89. Wang, W.; Devasthale, P.; Wang, A.; Harrity, T.; Egan, D.; Morgan, N.; Cap, M.; Fura, A.; Klei, H. E.; Kish, K.; Weigelt, C.; Sun, L.; Levesque, P.; Li, Y. X.; Zahler, R.; Kirby, M. S.; Hamann, L. G. 7-Oxopyrrolopyridinederived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site. Bioorg. Med. Chem. Lett., 2011, 21 (22), 6646-6651.
90. Schaffner, A. P.; Kaczanowska, K.; Wiesmuller, K. H. Design, Synthesis, and in Vitro Evaluation of Novel Aminomethyl-pyridines as DPP-4 Inhibitors. Acs Med. Chem. Lett., 2010, 1 (9), 530-535.
91. Miyamoto, Y.; Banno, Y.; Yamashita, T.; Fujimoto, T.; Oi, S.; Moritoh, Y.; Asakawa, T.; Kataoka, O.; Takeuchi, K.; Suzuki, N.; Ikedo, K.; Kosaka, T.; Tsubotani, S.; Tani, A.; Funami, M.; Amano, M.; Yamamoto, Y.; Aertgeerts, K.; Yano, J.; Maezaki, H. Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125. Bioorg. Med. Chem., 2011, 19 (1), 172-185.
92. Maezaki, H.; Miyamoto, Y. M., Y.; Banno, Y.; Yamashita, T.; Fujimoto, T.; Oi, S.; Moritoh, Y.; Asakawa, T.; Kataoka, O.; Yashiro, H.; Takeuchi, K.; Suzuki, N.; Ikedo, K.; Kosaka, T.; Tsubotani, S.; Tani, A.; Sasaki, M.; Funami, M.; Amano, M.; Yamamoto, Y.; Aertgeerts, K.; Yano, J. Discovery of a 3-Pyridylacetic Acid Derivative (TAK-100) as a Potent, Selective and Orally Active Dipeptidyl Peptidase IV (DPP-4) Inhibitor. J. Med. Chem., 2011, 54 (3), 831-850.
93. Rummey, C.; Nordhoff, S.; Thiemann, M.; Metz, G. In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg. Med. Chem. Lett., 2006, 16 (5), 1405-1409. (Pubitemid 43143031)
94. Wallace, M. B.; Feng, J.; Zhang, Z.; Skene, R. J.; Shi, L.; Caster, C. L.; Kassel, D. B.; Xu, R.; Gwaltney, S. L. Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2008, 18 (7), 2362-2367. (Pubitemid 351447287)
95. Coppola, G. M.; Zhang, Y. L.; Schuster, H. F.; Russell, M. E.; Hughes, T. E. 1-Aminomethylisoquinoline-4-carboxylates as novel dipeptidylpeptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2000, 10 (14), 1555-1558. (Pubitemid 30449718)
96. Lubbers, T.; Bohringer, M.; Gobbi, L.; Hennig, M.; Hunziker, D.; Kuhn, B.; Loffler, B.; Mattei, P.; Narquizian, R.; Peters, J. U.; Ruff, Y.; Wessel, H. P.; Wyss, P. 1, 3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2007, 17 (11), 2966-2970. (Pubitemid 46702649)
97. Boehringer, M.; Fischer, H.; Hennig, M.; Hunziker, D.; Huwyler, J.; Kuhn, B.; Loeffler, B. M.; Luebbers, T.; Mattei, P.; Narquizian, R.; Sebokova, E.; Sprecher, U.; Wessel, H. P. Aryl-and heteroaryl-substituted aminobenzo[a] quinolizines as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2010, 20 (3), 1106-1108.
98. Mattei, P.; Boehringer, M.; Di Giorgio, P.; Fischer, H.; Hennig, M.; Huwyler, J.; Kocer, B.; Kuhn, B.; Loeffler, B. M.; Macdonald, A.; Narquizian, R.; Rauber, E.; Sebokova, E.; Sprecher, U. Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett., 2010, 20 (3), 1109-1113.
99. Kuhlmann, O.; Paehler, A.; Weick, I.; Funk, C,; Pantze, M.; Zell, M.; Timm, U. Pharmacokinetics and metabolism of the dipeptidyl peptidase IV inhibitor carmegliptin in rats, dogs, and monkeys. Xenobiotica, 2010, 40 (12), 840-852.
100. Akiyama, T.; Abe, M.; Harada, S.; Kojima, F.; Sawa, R.; Takahashi, Y.; Naganawa, H.; Homma, Y.; Hamada, M.; Yamaguchi, A.; Aoyagi, T.; Muraoka, Y.; Takeuchi, T. Sulphostin, a potent inhibitor for dipeptidyl peptidase IV from Streptomyces sp. MK251-43F3. J. Antibiot. (Tokyo), 2001, 54 (9), 744-746. (Pubitemid 32962801)
101. Abe, M.; Abe, F.; Nishimura, C.; Ichimura, E.; Ogasawara, A.; Ichinei, M.; Muraoka, Y.; Saino, T. Sulphostin, a novel inhibitor of dipeptidyl peptidases IV (DPPIV) that stimulates hematopoiesis in mice. J. Antibiot. (Tokyo), 2005, 58 (2), 111-117. (Pubitemid 40410232)
102. Abe, M.; Akiyama, T.; Umezawa, Y.; Yamamoto, K.; Nagai, M.; Yamazaki, H.; Ichikawa, Y.; Muraoka, Y. Synthesis and biological activity of sulphostin analogues, novel dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem., 2005, 13 (3), 785-797. (Pubitemid 40093621)